Tao Huimin, Ph.D.

Position:Vice Chair of Orthopedics


Medical School:Zhejiang University School of Medicine, China

Academic Rank:Chief Physician


Clinical / Research Interests

Treatment of limb salvage, spine and pelvic malignant tumors

Professional Highlights

Zhejiang Medicine and Health Care Scientific and Technological Innovation Award, Second Prize, 2003

Zhejiang Medicine and Health Care Scientific and Technological Innovation Award, First Prize, 2001

Zhejiang Scientific and Technological Progress Award, Third Prize, 2000

Scientific and Technological Progress Award of Health Commission of Zhejiang Province, Second Prize, 1999

Professional Appointments

Member,  Bone Oncology Group, Chinses Society of Oncology, Chinese Medical Association, 2018-present  

Member, Sarcoma Committee, China Anti-Cancer Association, 2017-present

Member,  Bone and Soft Tissue Tumors Working Committee, Chinese Orthopedic Association, 2016-present

Member, Working Group of Tumors of the Spine, Pelvis and Limbs, 2016-present

Committee Member, Chinese Medical Education Association, 2018-present 

Vice Chair, Zhejiang Society of Pain, 2011-present

Education Experience

Research Summary

Dr. Tao is mainly engaged in immunotherapy, nanotherapy and targeted therapy of osteosarcoma. 


Zhu J(#), Wang Y, Yu W, Xia K, Huang Y, Wang J, Liu B, Tao H(*),Li F(*), Liang C(*): Long noncoding RNA: function and mechanism on differentiation of mesenchymal stem cells and embryonic stem cells. Curr Stem Cell Res Ther 2019; 14: 259-267. 

Wang Y(#), Yu W(#), Zhu J(#), Wang J, Xia K, Liang C, Tao H(*). Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. J Exp Clin Cancer Res 2019; 38: 168

Zhu J(#), Xia K(#), Yu W, Wang Y, Hua J, Liu B, Gong Z, Wang J, Xu A, You Z, Chen Q, Li F, Tao H, Liang C: Sustained release of gdf5 from a designed coacervate attenuates disc degeneration in a rat model. Acta Biomater 2019;86:300-311. 

Yu W(#), Wang Y(#), Zhu J(#), Jin L(#), Liu B, Xia K, Wang J, Gao J, Liang C, Tao H(*): Autophagy inhibitor enhance znpc/bsa nanoparticle induced photodynamic therapy by suppressing pd-l1 expression in osteosarcoma immunotherapy. Biomaterials 2018;192:128-139. 

Yu W(#), Ye M(#), Zhu J, Wang Y, Liang C, Tang J(*), Tao H(*), Shen Y: Zinc phthalocyanine encapsulated in polymer micelles as a potent photosensitizer for the photodynamic therapy of osteosarcoma. Nanomedicine 2018;14:1099-1110. 

Zhu J(#), Yu W(#), Liu B(#), Wang Y(#), Shao J, Wang J, Xia K, Liang C, Fang W, Zhou C, Tao H(*): Escin induces caspase-dependent apoptosis and autophagy through the ros/p38 mapk signalling pathway in human osteosarcoma cells in vitro and in vivo. Cell death & disease 2017;8:e3113. 

Zhu J(#), Zou H(#), Yu W, Huang Y, Liu B, Li T(*), Liang C(*), Tao H(*): Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells. Cancer Cell Int 2019;19:195. IF=3.439Zhang San; Li Si, Wang Wu, et al. Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Annals of Surgery, 2015,250(12): 31-35.

Current Program

The adoptive immunotherapy of osteosarcoma by using αβTCR gene transfection Vγ9V2Tcell in combination with fusion cell vaccine. Funding Source: National Natural Science Foundation of China.

The effects and mechanism of immunotherapy against osteosarcoma by genetically engineered anti-CD166-CAR T cells. Funding Source: Natural Science Fundation of Zhejiang.

Find People

Search by Family Name

Find A Department

Search by Departments